The estimated Net Worth of Michael J. La Barre is at least 17.6 百万$ dollars as of 27 August 2024. Dr Barre owns over 5,580 units of Halozyme Therapeutics stock worth over 10,319,369$ and over the last 14 years he sold HALO stock worth over 6,598,302$. In addition, he makes 710,181$ as Sr. VP & Chief Technical Officer at Halozyme Therapeutics.
Dr has made over 52 trades of the Halozyme Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,580 units of HALO stock worth 102,728$ on 27 August 2024.
The largest trade he's ever made was exercising 40,315 units of Halozyme Therapeutics stock on 1 July 2021 worth over 264,063$. On average, Dr trades about 12,699 units every 29 days since 2011. As of 27 August 2024 he still owns at least 173,756 units of Halozyme Therapeutics stock.
You can see the complete history of Dr Barre stock trades at the bottom of the page.
Dr. Michael J. LaBarre is the Sr. VP & Chief Technical Officer at Halozyme Therapeutics.
As the Sr. VP & Chief Technical Officer of Halozyme Therapeutics, the total compensation of Dr LaBarre at Halozyme Therapeutics is 710,181$. There are 3 executives at Halozyme Therapeutics getting paid more, with Helen Torley having the highest compensation of 5,857,130$.
Dr LaBarre is 57, he's been the Sr. VP & Chief Technical Officer of Halozyme Therapeutics since . There are 7 older and 2 younger executives at Halozyme Therapeutics. The oldest executive at Halozyme Therapeutics Inc. is Connie Matsui, 66, who is the Independent Chairman of the Board.
Michael's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130.
Over the last 17 years, insiders at Halozyme Therapeutics have traded over 92,345,799$ worth of Halozyme Therapeutics stock and bought 9,720,772 units worth 67,958,365$ . The most active insiders traders include Randal J Kirk、David A Ramsay、Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of 3,961,432$. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth 102,728$.
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Halozyme Therapeutics executives and other stock owners filed with the SEC include: